Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Oct 22 - Oct 27
Rated 5 out of 5 Priyanka D
The lack of success at Phase III was attributed to factors such as high baseline immunosuppressive therapy in patients and complex disease mechanisms in SLE, potentially limiting the application of Rituximab as a monotherapy in SLE (119)
Personal or family history of auto-immune disease for instance, thyroid disease, vitiligo, type 1 diabetes, Sjogrens disease (dry mouth and other symptoms), Addisons disease
JAMA Neurol
& Rechkemmer, G
US$ 26.01
US$ 24.60
US$ 21.42
US$ 20.29
